A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.

David PeterhoffVivian GlückMatthias VogelPhilipp SchusterAnja SchützPhilip NeubertVeruschka AlbertStefanie FrischMara KiesslingPhilip PervanMaren WernerNicole RitterLeon BablMaria DeichnerFrank HansesMatthias LubnowThomas MüllerDirk LunzFlorian HitzenbichlerFranz AudebertViola HähnelRobert OffnerMartina MüllerStephan SchmidRalph BurkhardtThomas GlückMichael KollerHans Helmut NillerBernhard GrafBernd SalzbergerJürgen J WenzelJonathan JantschAndré GessnerBarbara SchmidtRalf Wagner

Published in: Infection (2020)

With the described RBD-based ELISA protocol, we provide a reliable test for seroepidemiological surveys. Due to high specificity and strong correlation with virus neutralization, the RBD ELISA holds great potential to become a preferred tool to assess thresholds of protective immunity after infection and vaccination.

Keyphrases

sars cov
respiratory syndrome coronavirus
monoclonal antibody
randomized controlled trial
high throughput
cross sectional
human health
structural basis
risk assessment